DalsnaFinance

CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

Markets PR Newswire By PR Newswire 15 Jul 2026 12:45 1 min read
CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-led, global AI-agnostic path to evaluate and apply digital pathology, image analysis, spatial biology and precision diagnostics...

Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a single CRO-led, global AI-agnostic path to evaluate and apply digital pathology, image analysis, spatial biology and precision diagnostics...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.